Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis

Mantravadi, Santhi; George, Michael; Brensinger, Colleen M.; Du, Min; Baker, Joshua F.; Ogdie, Alexis

doi:10.1186/s41927-020-00138-3

Cited by 12 publications

(14 citation statements)

References 45 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study, HbA1c decreased after initiation of TNFi [median −0.35, interquartile range (IQR) 1.10–0.30] and MTX (median 0.40, IQR 1.20–0.30), and this reduction was about half (~ 0.4 units) the decrease observed after initiation of metformin. 80 …”

Section: Metabolic Disease In Psamentioning

confidence: 99%

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review

Karmacharya

Ogdie

Eder

2021

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is associated with a higher burden of cardiometabolic disorders, such as hypertension, dyslipidemia, diabetes, obesity, and cardiovascular disease (CVD), compared with the general population. These comorbidities are associated with the severity of disease, and adversely affect treatment outcomes in PsA. Comorbidities lead to increased physician visits and medications for patients and make the selection and maintenance of therapies challenging for physicians. Moreover, CVD is a leading cause of mortality in PsA. Therefore, optimal management of PsA should include not only treating the skin and joint disease, but also identifying comorbidities early, and managing them to improve long-term outcomes. Further studies are needed to understand the complex mechanisms, interactions, and trajectories of cardiometabolic comorbidities in psoriatic disease. Plain Language Summary Psoriatic arthritis and the association with cardiometabolic disease Psoriatic arthritis (PsA) is associated with a higher incidence and prevalence of cardiometabolic comorbidities compared with the general population, and higher than psoriasis and other inflammatory arthritides, such as rheumatoid arthritis and other spondyloarthritides. Obesity and hyperlipidemia are associated with an increased risk of developing PsA. Cardiometabolic comorbidities in PsA are associated with more severe disease and a lower likelihood of response to therapy. Suggested approaches to improve screening and management of CVD in PsA include education of family physicians and relevant specialists, development of mechanisms to improve communication between the rheumatologists and primary care providers, and novel models of care, including interdisciplinary cardio-rheumatology clinics.

show abstract

Section: Metabolic Disease In Psamentioning

confidence: 99%

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review

Karmacharya

Ogdie

Eder

2021

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

show abstract

“…The pleiotropic nature of TNF- α defines a broad potential for the treatment of autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, refractory asthma, and hidradenitis suppurativa. Strong evidence already supported that modulating the TNF- α pathway in patients with inflammatory rheumatic conditions and T2D could improve insulin sensitivity [ 45 ] and modestly lower HbA1c values [ 46 ].…”

Section: The Biological Rationale For Clinical Use Of Anticytokine Therapies In T2dmentioning

confidence: 99%

Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control

Velikova

Kabakchieva

Assyov

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity.

show abstract

“…Interestingly, biologic DMARDs administration in some JIA cases is associated with a significant improvement of HbA1c and better long-term metabolic control of diabetes. It should probably be recommended instead of GCS when it is possible [ 12 , 39 , 40 ]. Also, the patients receiving biologic DMARDs for JIA require less insulin therapy for diabetes [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Coincidence of juvenile idiopathic arthritis and type 1 diabetes: a case-based review

et al. 2022

View full text Add to dashboard Cite

The study was aimed to review a rare coexistence of type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA) regarding different clinical approaches to the management and treatment options. Medical complications of the two autoimmune disorders in children and adolescents have been evaluated, particularly in those treated with glucocorticosteroids (GCS) and insulin. A review of the literature regarding reports on concomitant T1D and JIA was conducted using resources available in Medline, Google Scholar, and Web of Science databases, with a specific focus on the combination of T1D and JIA in a pediatric population. The review was extended by our analysis of two patients treated in a single center for this comorbidity. Eligible reports of four cases were found, and including our two original records, a total of six pediatric patients (5 females) were analyzed, of which three had also other autoimmune diseases (thyroiditis, coeliac disease, autoimmune hepatitis), whereas four had been treated with a long-term GCS, and two were receiving biological therapy (etanercept or adalimumab). Only one of them had good metabolic control of diabetes. Diabetes in childhood may coexist with other autoimmune diseases, including rheumatologic conditions. Hyperglycemia can worsen JIA therapy by induction and maintaining inflammation. Using modern diabetes technologies (like personal insulin pumps and continuous glucose monitoring) helps to minimize the deteriorating effect of JIA exacerbations and the rheumatoid treatment on metabolic control of diabetes.

show abstract

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis

Cited by 12 publications

References 45 publications

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review

Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control

Coincidence of juvenile idiopathic arthritis and type 1 diabetes: a case-based review

Contact Info

Product

Resources

About